News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis

Study Status:

Active

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective of this study is to determine the efficacy and safety profiles of 2 doses and 2 dosing regimens of EYP001a versus placebo on liver fat content (LFC) from baseline to Week 12 in patients with NASH.

Information: 

Principal Investigator
Marcel Twahirwa, MD
Type of Trial
Prospective/Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram